news
Using albumin could facilitate vaccination by inhalation, finds pre-clinical study
MIT researchers developed and tested in mice intratracheal vaccines to protect against the vaccinia virus and the formation of lung cancer.
List view / Grid view
t-cells
article
How has COVID-19 impacted the development of cell and gene therapies?
European Pharmaceutical Review’s Hannah Balfour explores the findings of the Cell and Gene Therapy (CGT) Catapult’s 2020 advanced therapy medicinal product trials report and discusses how the European and global CGT markets are expected to perform in coming years.
news
CRISPR therapies could be one of the most transformative in human history, says GlobalData
Adam Pearson, Senior Oncology Analyst at GlobalData, comments on the development of CRISPR-based therapies and outlines potential opportunities and challenges in the space.
news
COVID-19 T cell test submitted for emergency use authorisation
In clinical testing, the T-SPOT.COVID test was found to agree with PCR test results in over 96 percent of samples taken within first 60 days of infection.
news
Ide-cel provides lasting remissions in multiply-relapsed myeloma
BMS and bluebird bio have applied to the FDA for approval of ide-cel as a standard therapy for relapsed or refractory multiple myeloma based on positive Phase II trial results.
news
CAR T therapy provides long-lasting remissions in non-hodgkin lymphoma
Study shows most non-Hodgkin's lymphoma patients who achieve a remission lasting one year remain in remission for five years after receiving Novartis’ Kymriah™.
article
Manufacturing of CAR T-cell therapies: an overview
The emergence of CAR T-cell therapies has ignited a revolution in the field of cancer treatments. While existing products show outstanding curative capability, they are hampered by significant clinical and commercial challenges, many of which stem from their manufacturing process. Maciej Nakoniecznik discusses how a combination of biological and technological advances…
article
Bioprocessing & Bioproduction In-Depth Focus 2021
In this in-depth focus, discover how biological and technological advances could enhance the clinical capabilities of CAR T-cell therapies and explore why clinicians need to be better educated about the development and licencing of biosimilars.
news
FDA approves third gene therapy for large B-cell lymphoma
Breyanzi (lisocabtagene maraleucel) was approved on the 54 percent complete remission rate achieved in diffuse large B-cell lymphoma trials.
news
Vaccine delivered via skin scarification could help fight respiratory diseases
According to a new study, vaccines delivered via skin scarification were better at inducing T cell activity in pre-clinical animal models.
news
NICE recommends new CAR T-cell therapy to treat mantle cell lymphoma
NICE has recommended that the CAR T-cell therapy Tecartus be given to patients with relapsed or refractory mantle cell lymphoma.
news
Innovations in CAR-T therapies in APAC will make market more competitive, report highlights
Research has shown that the CAR-T therapies in development in Asia-Pacific will make the worldwide market more competitive and drive down prices.
news
Intravenous delivery of TB vaccine found to dramatically improve potency in models
New research has shown that intravenous injection of the BCG vaccine dramatically reduces monkey susceptibility to TB bacteria and lung inflammation.
news
Global consortium formed to combat unproven cell banking services
The International Society for Cell and Gene Therapy has created a group to tackle the rising number of commercial cell bank services that are misleading patients.
video
On-demand webinar: Customer Case Study: Adaptimmune Implementing a Paperless QC Micro Laboratory
Learn how Adaptimmune, a leader in developing T cell cancer therapies, implemented Lonza’s MODA™ Solution to manage information in QC micro lab more efficiently.
